+86-28-82633987
Product name: Magnolin
Synonym name:
Catalogue No.: BP0915
Cas No.: 31008-18-1
Formula: C23H28O7
Mol Weight: 416.47
Botanical Source:
Physical Description:
Type of Compound: Lignans
Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.
The product could be supplied from milligrams to grams
Inquire for bulk scale.
Chengdu Biopurify Phytochemicals Ltd. is a leading company in the research, development, manufacture and marketing of High Quality Phytochemicals and Extracts(especially Active Ingredients from Traditional Chinese Medicine，TCM), Natural Active Pharmaceutical Ingredients worldwide.
The main services:
A. Supply active ingredients and reference standards of TCM, from mgs to kgs scale
B. Custom extraction and purification, target Herb Active Ingredients
C. Custom synthesis and semi-synthesis for Natural Active Ingredients
D. CR(contract research), CM(contract manufacture) and PD(process development) services from lab scale, pilot scale to commercial scale(GMP is also available)
E. TCM compounds library for drug screen,more than 3000 compounds available, many of them are rare and unique.
HPLC of Magnolin
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
64.6100
3.1698
3.1698
.0181
5.6882
11.3704
High
89.5450
3.5938
Yes
No
Yes
No
No
No
0.0
No
No
No
No
Magnolin is a natural compound isolated from Magnolia liliiflora, a plant of the genus Magnolia, and belongs to the magnolian class of compounds. In recent years, with the deepening of pharmacological activity research on natural products, magnolipin has gradually become a hot topic in pharmacology and natural medicinal chemistry research due to its remarkable bioactivity, especially its potential in antiviral and antitumor fields. Its main targeted signaling pathway is the Ras/ERKs/RSK2 pathway, which can exert various biological effects by inhibiting the activity of ERK1 and ERK2. Additionally, magnolipin exhibits potential inhibitory effects on various virus-related targets, demonstrating broad antiviral activity. This paper systematically reviews the chemical structure, plant origin, pharmacological activity, mechanism of action, druggability evaluation, and clinical application prospects of magnoline, aiming to provide theoretical basis and reference for related research.
The chemical formula of magnolenin is C_23H_28O_7, with a molecular weight of 416.4700. Its structural feature is a typical magnoline-based framework, containing multiple methoxy and hydroxyl substituents, which impart specific physicochemical properties. The LogP value of magnolipin was 3.1698, indicating moderate lipid solubility, which facilitates cell membrane penetration and distribution in the body. Its topological pole surface area (TPSA) is 64.6100, reflecting a moderate level of molecular polarity and possessing both hydrophilic and hydrophobic properties. Low water solubility (0.0181 mg/mL) suggests limited solubility in the aqueous phase but good lipid solubility, which facilitates oral absorption and blood-brain barrier penetration, the latter confirmed by experimental data. Magnolipin does not inhibit hERG channels, and the Ames-induced mutagenic test result is 0.0, indicating high safety and low toxicity risk.
Magnolin is mainly found in the root bark and flower buds of Magnolia liliiflora. Magnolia liliiflora, as a traditional Chinese medicinal herb, has a long history and is widely used in the field of traditional Chinese medicine. Its root bark and flower buds are rich in magnoliform compounds, with magnoliol being the main active ingredient.
Common methods for extracting magnolipin include solvent extraction, liquid-liquid separation, and chromatographic purification. Generally, ethanol or methanol is used as extraction solvents, and crude extracts are obtained by reflux extraction or ultrasound-assisted extraction. Subsequently, silica gel column chromatography and reversed-phase high-performance liquid chromatography (RP-HPLC) were used for separation and purification, ultimately obtaining high-purity magnoliacin. In recent years, the application of supercritical CO_2 extraction and microwave-assisted extraction technologies has improved extraction efficiency and purity, while making the process more environmentally friendly.
Magnolipin demonstrates broad activity in the antiviral field, exhibiting inhibitory effects on various virus-related targets. Its targets include myeloperoxidase (MPO), herpesvirus proteins UL42, UL54, ICP27, thymidine kinase (TK), viral glycoprotein gD, as well as HIV-related targets CCR5, CXCR4, HIV1 protease (HIV1-PR), and integrase (INT). Through multi-target action, magnolipin can interfere with viral replication, assembly, and invasion, demonstrating significant antiviral effects.
Relevant in vitro experiments have shown that magnolipin inhibits viruses such as herpes simplex virus (HSV) and human immunodeficiency virus (HIV), with low cytotoxicity and a good selectivity index. Additionally, magnolipin regulates the host's immune response, enhances antiviral defenses, and further enhances its antiviral potential.
Magnolenin inhibits ERK1 and ERK2 kinase activity (IC50 of 87 nM and 16.5 nM, respectively) by targeting the Ras/ERKs/RSK2 signaling pathway, blocking signals related to cell proliferation and metastasis, and demonstrates antitumor activity. This pathway is abnormally activated in various tumor cells, participating in cell cycle regulation, apoptosis inhibition, and cell migration. The inhibitory effect of magnoliin effectively blocks the growth and invasion of tumor cells, promoting apoptosis.
Multiple in vitro cell experiments and animal model studies support the anticancer potential of magnolipin in various tumors, including lung cancer, breast cancer, and colorectal cancer. Its mechanism involves inhibiting RSK2 kinase downstream of the ERK signaling pathway, regulating the expression of cyclin and apoptosis-related proteins, and enhancing cell sensitivity to chemotherapy drugs.
In addition to antiviral and antitumor effects, magnolipin also exhibits anti-inflammatory, antioxidant, and neuroprotective effects. It can inhibit the release of inflammatory mediators, reduce oxidative stress damage, and protect nerve cells from injury. These effects provide a theoretical basis for its application in neurodegenerative and chronic inflammatory diseases.
The core mechanism of action of magnolil is targeting the Ras/ERKs/RSK2 signaling pathway. This pathway plays a key regulatory role in cell proliferation, differentiation, migration, and survival. Magnolenin directly binds to and inhibits the activities of ERK1 and ERK2 kinases, blocking their phosphorylation and downstream signaling, thereby suppressing RSK2 kinase activation. RSK2, as a key effector in the ERK signaling pathway, regulates various transcription factors and cyclins. The inhibitory effect of magnolipin leads to cell cycle arrest and apoptosis.
In terms of antiviral effects, magnolinein interferes with viral protein function and replication processes through multi-target synergistic action. For example, inhibiting UL42 and UL54 proteins affects viral DNA replication, inhibiting ICP27 interferes with viral gene expression, and blocking TK and gD proteins from affecting viral invasion and spread. Inhibition of HIV-related targets CCR5 and CXCR4, blocking the virus from entering host cells, demonstrating its multidimensional antiviral mechanism.
Additionally, magnolipin has a regulatory effect on the host immune system, enhancing antiviral immune responses and reducing the risk of viral escape.
Magnolysin has good druggability parameters. Its molecular weight of 416.47 meets the Lipinski rule, and the LogP value of 3.17 is moderate, indicating good membrane permeability and oral bioavailability. TPSA is 64.61, supporting its blood-brain barrier penetration ability and suitable for treating central nervous system diseases.
Low water solubility is a major challenge to its druggability, which may limit its oral absorption and internal distribution. To address this, researchers have attempted to improve drug delivery systems such as nanocarriers, liposomes, and solid dispersions to improve their solubility and bioavailability.
In terms of safety, magnolil does not inhibit hERG channels, reducing the risk of cardiotoxicity. A negative Ames test indicates no significant mutagenicity, indicating high safety. Preliminary pharmacokinetic studies show that magnolipin has a long half-life and good tissue distribution in the body, especially at high concentrations in brain tissue, supporting its neuroprotective potential.
Based on magnoline's significant activity in antiviral and antitumor fields, its clinical application prospects are broad. Currently, magnolipin is still in the preclinical research stage, and systematic pharmacokinetics, toxicology, and clinical trials are needed to verify its safety and efficacy.
In the field of antiviral treatment, magnolipin is expected to become a multi-target antiviral drug, especially for the treatment of herpes virus and HIV. Its multi-target mechanism helps reduce the risk of resistance and improve treatment outcomes.
In tumor treatment, magnoliline has potential as a targeted therapy drug by inhibiting key signaling pathways. When used in combination with existing chemotherapy drugs, it may enhance efficacy and reduce side effects. Moreover, its excellent blood-brain barrier penetration gives it unique advantages in treating brain tumors and neurological diseases.
Future research should focus on structural modification of magnolipin and the development of drug delivery systems to improve its water solubility and bioavailability; At the same time, it deeply analyzes its molecular mechanisms to expand its indication range. Multidisciplinary collaboration will accelerate the clinical translation of magnoline.
Magnolian, as the main active ingredient in Magnolia liliiflora, demonstrates great potential in antiviral and antitumor fields due to its unique chemical structure and multi-target pharmacological activity. By targeting the Ras/ERKs/RSK2 signaling pathway, it regulates cell proliferation and apoptosis, exerting anti-tumor effects; At the same time, it inhibits viral proteins with multiple targets, enhances host immunity, and demonstrates broad-spectrum antiviral capabilities. Good druggability parameters and safety have laid the foundation for its clinical development. Although challenges in water solubility and pharmacokinetics still remain, through the application of modern drug design and delivery technologies, magnolipin is expected to become a new generation of natural product drugs, offering new strategies and options for antiviral and anti-tumor treatments. Future systematic research and clinical validation will further reveal its clinical application value and drive its advancement toward clinical translation.
Shenshuai
Wenjing
Hedandan
